A5053899444- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- HIV/AIDS drug development and treatment
- Biosimilars and Bioanalytical Methods
- Chronic Lymphocytic Leukemia Research
- Liver Disease and Transplantation
- Venous Thromboembolism Diagnosis and Management
- Epilepsy research and treatment
- Pharmaceutical Economics and Policy
- Acute Myocardial Infarction Research
- Hepatitis B Virus Studies
- Pharmacological Effects and Toxicity Studies
- Erythropoietin and Anemia Treatment
- Urinary Tract Infections Management
- Blood transfusion and management
- Pelvic floor disorders treatments
- Urinary Bladder and Prostate Research
- Infectious Encephalopathies and Encephalitis
- Blood Pressure and Hypertension Studies
- Diabetes Management and Education
- Chronic Kidney Disease and Diabetes
- Polyomavirus and related diseases
- Diet, Metabolism, and Disease
Institute for Clinical and Economic Review
2024
Cornell University
2023
Weill Cornell Medicine
2023
Jacksonville College
2023
Mayo Clinic in Florida
2023
WinnMed
2023
Bowie State University
2023
GlaxoSmithKline (Canada)
2012
Analysis Group (United States)
2012
Emory University
2012
This study evaluated the effects of initial versus delayed treatment with a drug combination on blood pressure (BP) control and risk cardiovascular (CV) events in hypertensive patients. Clinical trials suggest that time to BP is an important determinant long-term outcomes, but real-world evidence scarce. Using electronic medical charts (2005–2009), we retrospectively analyzed 1762 adult patients elevation initiating therapy matched 1:1 similar monotherapy later switched therapy. Incidence...
<h3>Objective:</h3> To quantify the clinical and economic burden of uncontrolled epilepsy in patients requiring emergency department (ED) visit or hospitalization. <h3>Methods:</h3> Health insurance claims from a 5-state Medicaid database (1997Q1–2009Q2) 55 self-insured US companies ("employer," 1999Q1 2008Q4) were analyzed. Adult with receiving antiepileptic drugs (AED) selected. Using retrospective matched-cohort design, categorized into cohorts "uncontrolled" (≥2 changes AED therapy, then...
Background Glofitamab is a T-cell engaging bispecific monoclonal antibody that was granted accelerated approval from the United States Food and Drug Administration for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified arising follicular lymphoma, after ≥2 lines of systemic therapy (3L+).
Mosunetuzumab has received accelerated approval by the US Food and Drug Administration for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two more lines of systemic therapy. We evaluated cost-effectiveness mosunetuzumab treatment R/R FL from a private payer perspective.
Aims This study assessed the budget impact of resmetirom as a treatment for adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) moderate-to-advanced liver fibrosis and estimated total costs hypothetical private payer in United States.
Objective: This study compared the cost-effectiveness of direct-acting antiviral therapies currently recommended for treating genotypes (GT) 1 and 4 chronic hepatitis C (CHC) patients in US.Methods: A analysis treatments CHC from a US payer's perspective over lifelong time horizon was performed. Markov model based on natural history used population that included treatment-naïve -experienced patients. Treatment alternatives considered GT1 ombitasvir/paritaprevir/ritonavir + dasabuvir ±...
This study aimed to assess the total cost of care (TCC) and budget impact introducing 12-month fixed duration venetoclax + obinutuzumab (VEN+G) as first-line treatment for chronic lymphocytic leukemia (CLL) from perspective a US health plan with 1,000,000 (1M) members. The 3-year model included following comparators: fludarabine cyclophosphamide rituximab (FCR), bendamustine (BR), chlorambucil (GClb), ibrutinib (Ibr), Ibr+Rituximab/obinutuzumab [Ibr+R/Ibr+G]). TCC US-specific costs...
Objectives: To estimate clinical outcomes and cost-effectiveness of ombitasvir/paritaprevir/ritonavir dasabuvir ± ribavirin (OMB/PTV/r + DSV RBV) compared with treatment regimens including pegylated interferon (PegIFN) for patients chronic genotype 1 hepatitis C virus (HCV) infection.Methods: An Excel spreadsheet Markov model tracking progression through stages liver disease was developed. Costs patient utilities were taken from published studies. Rates based on studies untreated HCV...
This study aimed to assess the budget impact of introducing fixed-duration mosunetuzumab as a treatment option for adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies and estimate total cumulative costs per patient in USA. A 3-year model was developed hypothetical 1-million-member cohort enrolled mixed commercial/Medicare health plan. Comparators were: axicabtagene ciloleucel, tisagenlecleucel, tazemetostat, rituximab plus lenalidomide,...
Background: Clinical trials have shown that self-monitoring of blood glucose (SMBG) combined with patient education and medication titration can lead to improved glycated hemoglobin (HbA1c) reduced weight in recently diagnosed non-insulin-treated type 2 diabetes mellitus (T2DM) patients. This retrospective matched cohort study assessed the association SMBG achieving long-term clinical outcomes these patients a real-world setting. Methods: Using electronic medical records (2008–2011), we...
The aim of this study was to evaluate the cost effectiveness mirabegron relative two antimuscarinics, oxybutynin extended release (ER) and tolterodine ER, in patients with overactive bladder (OAB) from perspective a third-party payer Colombia. A Markov model simulated therapeutic management, disease course, complications hypothetical cohorts OAB over 5-year period. predicted costs three outcomes: quality-adjusted life-years (QALYs), micturition state improvement (MSI), incontinence (ISI). In...
This study reports the long-term cost per sustained virologic response (SVR) with Viekira Pak (ombitasvir, paritaprevir and ritonavir, dasabuvir) without ribavirin standard of care in US, including sofosbuvir plus simeprevir (SOF+SMV) peg-interferon (SOF+PR), among patients genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. A Markov cost-effectiveness model was used to estimate HCV. The analysis modeled independent cohorts GT1 HCV over a lifetime horizon annual cycles from US payer...